Drugs that act on calcitonin gene-related peptide are the first category of pharmaceuticals developed as targeted therapy for migraine prevention. Data presented this week at the 9 th Congress of the European Academy of Neurology in Budapest reinforced that they represent a new era of migraine treatment, and they offer ...
EAN 2023 – CGRP-targeting Drugs: A New Era of Migraine Treatment
Moheb Costandi
|
Conference Report
|
05 July 2023
Register or log in to read more
Registration is free and easy, giving you complete access to all Univadis content.
Create a Free Account I have an account